Bispecific antibody · developed by Pfizer
Tilrekimig (PF-07275315) is a drug studied in moderate to severe chronic obstructive pulmonary disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07839884 | Phase 3 | Moderate to Severe Chronic Obstructive Pulmonary Disease | Recruiting | PFE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Moderate to Severe Chronic Obstructive Pulmonary Disease
See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PFE catalysts and pipeline →